

Part VI: Summary of the risk management plan

Summary of risk management plan for Buspirone, Buripal tablets:

This is a summary of the risk management plan (RMP) for Buripal tablets. The RMP details important risks of Buripal, how these risks can be minimised, and how more information will be obtained about Buripal's risks and uncertainties (missing information).

Buripal summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Buripal should be used.

I. The medicine and what it is used for

Buripal is authorised for the symptomatic treatment of anxiety states of clinically relevant severity with the following cardinal symptoms: anxiety, agitation, tension.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Buripal, together with measures to minimise such risks and the proposed studies for learning more about Buripal's risks, are outlined below.

Measures to minimize the risks identified for medicinal products are:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorized pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g., with or without prescription) can help to minimize its risks.

Together, these measures constitute routine risk minimization measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A *List of important risks and missing information*

Important risks of Buripal are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use Buripal. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B *Summary of important risks*

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C *Post-authorisation development plan*

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Buripal.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Buripal.